[Editor's note: The global market for products in the management of obesity has been analyzed in the 2011 Report #S835, which supersedes the content discussed below.]
The revenues to be had from the clinical management of obesity, whether derived from pharmaceutical or device sales, are forecast to see double-digit growth through 2015. Although revenues have been dampened by the FDA’s negative reaction to Sanofi-Aventis’ application for rimonabant, there are other drug compounds in late stages of testing which may prove to be blockbuster drugs, and should see launch during the forecast period. Allergan’s LapBand device will soon be facing competition from Ethicon Endo-Surgery’s version, and other devices should soon be providing surgeons and patients with yet other alternatives to bypass surgery and adjustable gastric banding. Below are shown the absolute and relative growth rates in drug and device revenues for the clinical management of obesity.
The increase in sales is based upon the net effect of a number of factors, including:
- Increasing attention paid by governments, public health systems, physicians and patients to the enormity of the obesity problem and to its growth rate
- The introduction of new medical devices via regulatory approval in the US and EU, and their subsequent acceptance by physicians and their patients
- Regulatory approvals and market launch of new, more effective drugs with relatively more acceptable adverse side effects
- Increase in the number of overweight, obese and morbidly obese individuals worldwide, and an increase in the percentage of eligible patients who seek treatment
- Increased reimbursement for surgery, pharmaceutical treatments, and combinations thereof.
The relative growth of revenues for drugs and devices are driven by the projected penetration of new products, with shifts anticipated in the forecast period to 2015. _________________ From Report #S825, "Worldwide Market for the Clinical Management of Obesity, 2007." >>> See the 2011 report #S835.